AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15876664 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound probability density function parameters including the speckle factor and K distribution parameter
Number of subjects: 198
Study 12081825 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate beverage (35.1 kJ/kg)
Number of subjects: 143
Study 12081825 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% carbohydrate beverage (70.2 kJ/kg)
Number of subjects: 143
Study 12081825 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 143
Study 12081825 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation
Number of subjects: 143
Study 12081825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 10732589 — intervention group
Group type: EXPERIMENTAL
Intervention: Respirator
Number of subjects: 26
Study 10732589 — intervention group
Group type: COMPARATOR
Intervention: Manual resuscitator
Number of subjects: 26
Study 7828131 — intervention group
Group type: COMPARATOR
Intervention: VAD (vincristine, doxorubicin, and dexamethasone)
Number of subjects: 0
Study 7828131 — intervention group
Group type: EXPERIMENTAL
Intervention: VAD plus oral verapamil (VAD/v)
Number of subjects: 0
Study 1964218 — intervention group
Group type: EXPERIMENTAL
Intervention: Local step-by-step intrapulmonary administration of glucocorticosteroids (GCS)
Number of subjects: 61
Study 1964218 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 61
Study 6153310 — intervention group
Group type: EXPERIMENTAL
Intervention: ajmalin
Number of subjects: 15
Study 6153310 — intervention group
Group type: EXPERIMENTAL
Intervention: propafenon
Number of subjects: 15
Study 6153310 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine
Number of subjects: 15
Study 6153310 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 6001
Number of subjects: 15
Study 6153310 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 30704885 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle transpatellar tunnel technique (group A)
Number of subjects: 91
Study 30704885 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-anchor anatomic reconstruction technique (group B)
Number of subjects: 91
Study 31406735 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical documentaries (experimental group)
Number of subjects: 277
Study 31406735 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 277
Study 27180210 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial Direct Current Stimulation (atDCS) over left pMTG/STG
Number of subjects: 24
Study 27180210 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial Direct Current Stimulation (atDCS) over left LIFG
Number of subjects: 24
Study 27180210 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study 24411286 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided compression (UGC)
Number of subjects: 80
Study 24411286 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided para-aneurysmal saline injection (PASI)
Number of subjects: 80
Study 22101224 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercising Together - a progressive, supervised strength training program
Number of subjects: 64
Study 22101224 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 64
Study 19576776 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted plantarflexor push off
Number of subjects: 11
Study 19576776 — intervention group
Group type: EXPERIMENTAL
Intervention: Resisted plantarflexor push off
Number of subjects: 11
Study 19576776 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no assistance or resistance)
Number of subjects: 11
Study 18042570 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 0
Study 18042570 — intervention group
Group type: COMPARATOR
Intervention: Reference exposure
Number of subjects: 0
Study 15220031 — intervention group
Group type: EXPERIMENTAL
Intervention: donepezil (5 mg/day)
Number of subjects: 565
Study 15220031 — intervention group
Group type: COMPARATOR
Intervention: donepezil (5 or 10 mg/day)
Number of subjects: 565
Study 11468604 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (received a free 5-day course of prednisone, transportation vouchers, and a 48-hour telephone reminder)
Number of subjects: 192
Study 11468604 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 192
Study 9683718 — intervention group
Group type: EXPERIMENTAL
Intervention: iodixanol (Visipaque; 320 mg I/ml)
Number of subjects: 398
Study 9683718 — intervention group
Group type: COMPARATOR
Intervention: iohexol (Omnipaque; 300 mg I/ml)
Number of subjects: 398
Study 9683718 — intervention group
Group type: EXPERIMENTAL
Intervention: Both iodixanol and iohexol
Number of subjects: 398
Study 8023589 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 102
Study 8023589 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX)
Number of subjects: 102
Study 8023589 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal antiinflammatory drugs (NSAID)
Number of subjects: 102
Study 3072358 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg
Number of subjects: 0
Study 3072358 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 50 mg
Number of subjects: 0
Study 3072358 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 150 mg
Number of subjects: 0
Study 3072358 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 75 mg
Number of subjects: 0
Study 3072358 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 225 mg
Number of subjects: 0
Study 31379311 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Recovery Therapy (SRT)
Number of subjects: 75
Study 29211509 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dosing of antihypertensive medications
Number of subjects: 79
Study 29211509 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening dosing of antihypertensive medications
Number of subjects: 79
Study 28727372 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin
Number of subjects: 110
Study 28727372 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 110
Study 26678640 — intervention group
Group type: EXPERIMENTAL
Intervention: LAA ligation and PVI
Number of subjects: 600
Study 26678640 — intervention group
Group type: COMPARATOR
Intervention: PVI alone
Number of subjects: 600
Study 23422867 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone soy protein (ISP) supplementation, 154 mg daily for 3 years
Number of subjects: 224
Study 23422867 — intervention group
Group type: COMPARATOR
Intervention: Placebo (milk protein-matched)
Number of subjects: 224
Study 23422867 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone soy protein (ISP) supplementation
Number of subjects: 224
Study 23422867 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone soy protein (ISP) supplementation and Placebo
Number of subjects: 224
Study 21349449 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual practitioner coach
Number of subjects: 30
Study 21349449 — intervention group
Group type: EXPERIMENTAL
Intervention: Video practitioner coach
Number of subjects: 30
Study 21349449 — intervention group
Group type: COMPARATOR
Intervention: No coach
Number of subjects: 30
Study 19371188 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy
Number of subjects: 0
Study 19371188 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose statin therapy
Number of subjects: 0
Study 16421655 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report Health Risk Assessment (HRA)
Number of subjects: 176
Study 16421655 — intervention group
Group type: COMPARATOR
Intervention: HRA with measurement of cardiovascular (CVD) health indicators
Number of subjects: 176
Study 14503436 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight‐supported treadmill training (BWSTT) combined with over‐ground locomotor retraining
Number of subjects: 146
Study 14503436 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy program for mobility
Number of subjects: 146
Study 10797496 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen blockade in addition to radiotherapy
Number of subjects: 0
Study 10797496 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen blockade at diagnosis
Number of subjects: 0
Study 10797496 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer screening
Number of subjects: 0
Study 10797496 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment for localized prostate cancer
Number of subjects: 0
Study 10797496 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of localized disease
Number of subjects: 0
Study 10797496 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening procedures and treatments for localized prostate cancer
Number of subjects: 0
Study 9094060 — intervention group
Group type: EXPERIMENTAL
Intervention: Silent cerebral infarction
Number of subjects: 88
Study 9094060 — intervention group
Group type: EXPERIMENTAL
Intervention: Silent cerebral infarction (more advanced grades)
Number of subjects: 88
Study 9094060 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute cerebral infarction (within 3 days after onset)
Number of subjects: 88
Study 9094060 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute cerebral infarction (1 month after onset)
Number of subjects: 88
Study 9094060 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic cerebral infarction
Number of subjects: 88
Study 1443705 — intervention group
Group type: EXPERIMENTAL
Intervention: M-K-A (midazolam 0.5 mg/kg, ketamine 3 mg/kg, atropine 0.02 mg/kg)
Number of subjects: 100
Study 1443705 — intervention group
Group type: EXPERIMENTAL
Intervention: M-A (midazolam 0.5 mg/kg, atropine 0.02 mg/kg)
Number of subjects: 100
Study 1443705 — intervention group
Group type: EXPERIMENTAL
Intervention: K-A (ketamine 3 mg/kg, atropine 0.02 mg/kg)
Number of subjects: 100
Study 1443705 — intervention group
Group type: COMPARATOR
Intervention: A (atropine 0.02 mg/kg)
Number of subjects: 100
Study 1443705 — intervention group
Group type: EXPERIMENTAL
Intervention: M-K-A
Number of subjects: 100
Study 1443705 — intervention group
Group type: EXPERIMENTAL
Intervention: M-A
Number of subjects: 100
Study 1443705 — intervention group
Group type: EXPERIMENTAL
Intervention: M-A or M-K-A
Number of subjects: 100
Study 1443705 — intervention group
Group type: EXPERIMENTAL
Intervention: K-A
Number of subjects: 100
Study 1443705 — intervention group
Group type: COMPARATOR
Intervention: A
Number of subjects: 100
Study 2947100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract
Number of subjects: 103
Study 2947100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 29949323 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified natural ovulation cycle with HCG (n=32)
Number of subjects: 123
Study 29949323 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hormonally stimulated cycle by low dose Clomiphene Citrate (n=30)
Number of subjects: 123
Study 29949323 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial cycle induced with estradiol and progesterone supplementation (n=61)
Number of subjects: 123
Study 29949323 — intervention group
Group type: COMPARATOR
Intervention: Comparison of endometrial thickness
Number of subjects: 123
Study 26450116 — intervention group
Group type: EXPERIMENTAL
Intervention: Task Concentration Training (TCT)
Number of subjects: 82
Study 26450116 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 82
Study 26450116 — intervention group
Group type: EXPERIMENTAL
Intervention: TCT-CT and CT-TCT sequences
Number of subjects: 82
Study 26450116 — intervention group
Group type: COMPARATOR
Intervention: Waiting list condition
Number of subjects: 82
Study 24889213 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-month outpatient rehabilitation program
Number of subjects: 21
Study 24889213 — intervention group
Group type: COMPARATOR
Intervention: Usual postoperative care
Number of subjects: 21
Study 21956607 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil therapy
Number of subjects: 77
Study 21956607 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 77
Study 19966584 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-body isometric muscle resistance exergaming (EXP) during solo play
Number of subjects: 32
Study 19966584 — intervention group
Group type: COMPARATOR
Intervention: Conventional handheld controller (CON) during solo play
Number of subjects: 32
Study 18405874 — intervention group
Group type: COMPARATOR
Intervention: Two relaxing incisions in the left eye and no incisions in the right eye
Number of subjects: 100
Study 18405874 — intervention group
Group type: COMPARATOR
Intervention: Three relaxing incisions in the left eye and no incisions in the right eye
Number of subjects: 100
Study 18405874 — intervention group
Group type: COMPARATOR
Intervention: No incisions in the right eye
Number of subjects: 100
Study 15793026 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional aggregate scoring method on a five-point Likert-based scale
Number of subjects: 85
Study 15793026 — intervention group
Group type: COMPARATOR
Intervention: Four alternate scoring methods (including single-best-answer scoring methods)
Number of subjects: 85
Study 15793026 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-best-answer scoring with three answer choices
Number of subjects: 85
Study 12435668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) infusion of 400 mg ciprofloxacin over 60 min
Number of subjects: 8
Study 12435668 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral (p.o.) dose of 500 mg ciprofloxacin
Number of subjects: 8
Study 12435668 — intervention group
Group type: COMPARATOR
Intervention: Both i.v. and p.o. ciprofloxacin
Number of subjects: 8
Study 12435668 — intervention group
Group type: COMPARATOR
Intervention: In vitro model simulating in vivo pharmacokinetics
Number of subjects: 8
Study 10357120 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort oral drops
Number of subjects: 18
Study 10357120 — intervention group
Group type: COMPARATOR
Intervention: Deflazacort oral tablets
Number of subjects: 18
Study 8706449 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract
Number of subjects: 4142
Study 1902557 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary nursing
Number of subjects: 0
Study 1902557 — intervention group
Group type: COMPARATOR
Intervention: Team nursing
Number of subjects: 0
Study 6787746 — intervention group
Group type: EXPERIMENTAL
Intervention: High voltage therapy of the retrobulbar region
Number of subjects: 83
Study 31508656 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucalyptus grandis (8 years after transplant)
Number of subjects: 7
Study 31508656 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucalyptus grandis (6 years after transplant)
Number of subjects: 7
Study 31508656 — intervention group
Group type: COMPARATOR
Intervention: Soil Naked (control)
Number of subjects: 7
Study 31508656 — intervention group
Group type: COMPARATOR
Intervention: Native Forest (control)
Number of subjects: 7
Study 30683945 — intervention group
Group type: EXPERIMENTAL
Intervention: IIGI+GLP-1 (1 pmol kg-1 min-1)
Number of subjects: 17
Study 30683945 — intervention group
Group type: EXPERIMENTAL
Intervention: IIGI+GIP (4 pmol kg-1 min-1)
Number of subjects: 17
Study 30683945 — intervention group
Group type: EXPERIMENTAL
Intervention: IIGI+GIP+GLP-1 (4 and 1 pmol kg-1 min-1)
Number of subjects: 17
Study 30683945 — intervention group
Group type: COMPARATOR
Intervention: IIGI+saline (154 mmol/l NaCl; placebo)
Number of subjects: 17
Study 28505519 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive situated and simulated teaching (ISST)
Number of subjects: 31
Study 28505519 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-ISST)
Number of subjects: 31
Study 25154888 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative cholangiography (IOC)
Number of subjects: 132
Study 25154888 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative choledochoscopy (Group B)
Number of subjects: 132
Study 24073975 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 1500
Study 24073975 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil 50 mg
Number of subjects: 1500
Study 24073975 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg and 50 mg
Number of subjects: 1500
Study 20720408 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbecue maneuver + forced prolonged position (FPP)
Number of subjects: 147
Study 20720408 — intervention group
Group type: COMPARATOR
Intervention: Gufoni maneuver
Number of subjects: 147
Study 20720408 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbecue maneuver + FPP
Number of subjects: 147
Study 19169684 — intervention group
Group type: EXPERIMENTAL
Intervention: Fotemustine (100-75 mg/m2) administered every three weeks followed by fotemustine (100 mg/m2) every three weeks after a 5-week rest for up to 1 year.
Number of subjects: 43
Study 19169684 — intervention group
Group type: EXPERIMENTAL
Intervention: Fotemustine in patients with methylated MGMT promoter status.
Number of subjects: 43
Study 19169684 — intervention group
Group type: EXPERIMENTAL
Intervention: Fotemustine in patients with unmethylated MGMT promoter status.
Number of subjects: 43
Study 19169684 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction phase of fotemustine treatment.
Number of subjects: 43
Study 19169684 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance phase of fotemustine treatment.
Number of subjects: 43
Study 16755856 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilarinum in addition to conventional treatment (beta‐adrenoblockers, antiaggregants, and statins)
Number of subjects: 130
Study 16755856 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 130
Study 15217659 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 72
Study 15217659 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 72
Study 12231081 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 2061
Study 9823645 — intervention group
Group type: EXPERIMENTAL
Intervention: Artroflow device used three times a day for 30 minutes in addition to Enoxaparin 1 x 40 mg subcutaneously per day.
Number of subjects: 160
Study 9823645 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only Enoxaparin 1 x 40 mg subcutaneously per day.
Number of subjects: 160
Study 7650190 — intervention group
Group type: EXPERIMENTAL
Intervention: BamHI‐W PCR assay
Number of subjects: 24
Study 2560621 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus adjuvant chemotherapy (n = 8)
Number of subjects: 16
Study 2560621 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy
Number of subjects: 16
Study 785735 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg matrix isoniazid
Number of subjects: 0
Study 785735 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of matrix isoniazid
Number of subjects: 0
Study 785735 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-40 mg/kg matrix isoniazid
Number of subjects: 0
Study 31340793 — intervention group
Group type: COMPARATOR
Intervention: Low altitude (LA) rehabilitation
Number of subjects: 50
Study 31340793 — intervention group
Group type: COMPARATOR
Intervention: High altitude (HA) rehabilitation
Number of subjects: 50
Study 31340793 — intervention group
Group type: COMPARATOR
Intervention: Comparison of HA vs. LA
Number of subjects: 50
Study 27862308 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab consolidation therapy (10 mg intravenously once weekly for 8 weeks, escalating in 10 mg intervals)
Number of subjects: 13
Study 27862308 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab consolidation therapy
Number of subjects: 13
Study 25481662 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative concurrent chemoradiotherapy (CRT) with 4 courses of intravenous carboplatin and oral vinorelbine, plus radiotherapy (42 Gy in 15 fractions)
Number of subjects: 42
Study 25481662 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 42
Study 23774931 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (TCI) of propofol and remifentanil
Number of subjects: 160
Study 23774931 — intervention group
Group type: COMPARATOR
Intervention: Manual-controlled infusion (MCI) of propofol and remifentanil
Number of subjects: 160
Study 21627767 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-TENS therapy
Number of subjects: 22
Study 21627767 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 22
Study 19366842 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human luteinizing hormone (rhLH)
Number of subjects: 9
Study 19366842 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human chorionic gonadotropin (rhCG)
Number of subjects: 9
Study 19366842 — intervention group
Group type: COMPARATOR
Intervention: follicle-stimulating hormone (FSH)
Number of subjects: 9
Study 17122575 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 42
Study 17122575 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 42
Study 17122575 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium-Ketamine
Number of subjects: 42
Study 17122575 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study 15577646 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir (ATV)
Number of subjects: 30
Study 15577646 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 30
Study 15577646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11733092 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile release tablets containing 60 mg DIL
Number of subjects: 8
Study 11733092 — intervention group
Group type: COMPARATOR
Intervention: Conventional tablets
Number of subjects: 8
Study 9390586 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA) with bupivacaine 0.125% and fentanyl 10 microg/mL
Number of subjects: 124